Fig. 1From: Saliva‑microbiome‑derived signatures: expected to become a potential biomarker for pulmonary nodules (MCEPN-1)A prospective, non-randomized, concurrent controlled trial (MCEPN-1) found oral microbiome characteristics and function between healthy individuals and pulmonary nodule patientsBack to article page